{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:57:51Z","timestamp":1790758671856,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.intimp.2020.106655","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T05:20:25Z","timestamp":1591507225000},"page":"106655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative phenotypes of peripheral blood and spleen cells from cancer patients"],"prefix":"10.1016","volume":"85","author":[{"given":"Kathryn E.","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan P.","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn M.","family":"Stromnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Padussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Talmadge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106655_b0005","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2020.106655_b0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","article-title":"Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.intimp.2020.106655_b0015","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cyoung\u201c tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2020.106655_b0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0b013e31824d4465","article-title":"Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook","volume":"18","author":"Wu","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.intimp.2020.106655_b0025","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2020.106655_b0030","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00262-005-0118-2","article-title":"Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites","volume":"55","author":"Harlin","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2020.106655_b0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-3083.2011.02640.x","article-title":"Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution","volume":"75","author":"Donia","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0040","doi-asserted-by":"crossref","first-page":"2511-","DOI":"10.1200\/jco.2012.30.15_suppl.2511","article-title":"Costimulatory effect of agonistic 4\u20131BB antibody on proliferation and effector phenotype of tumor-infiltrating lymphocytes in melanoma","volume":"30","author":"Sarnaik","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2020.106655_b0045","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00262-016-1826-5","article-title":"Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma","volume":"65","author":"Noble","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2020.106655_b0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","article-title":"Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer","volume":"58","author":"Leffers","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2020.106655_b0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2172-11-19","article-title":"Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients","volume":"11","author":"Deschoolmeester","year":"2010","journal-title":"BMC Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0060","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2020.106655_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jss.2011.03.068","article-title":"Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer","volume":"171","author":"Horne","year":"2011","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.intimp.2020.106655_b0070","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archsurg.2012.35","article-title":"Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer","volume":"147","author":"Huh","year":"2012","journal-title":"Arch. Surg."},{"key":"10.1016\/j.intimp.2020.106655_b0075","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.4049\/jimmunol.1300538","article-title":"Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy","volume":"191","author":"Turcotte","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0080","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI82416","article-title":"Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes","volume":"125","author":"Cohen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2020.106655_b0085","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/cas.12502","article-title":"PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer","volume":"105","author":"Waki","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2020.106655_b0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-016-0164-7","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors","volume":"4","author":"Hall","year":"2016","journal-title":"J. Immuno Ther. Cancer"},{"key":"10.1016\/j.intimp.2020.106655_b0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2018.05.024","article-title":"Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies","volume":"150","author":"Mayor","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2020.106655_b0100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2020.106655_b0105","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-15-2657","article-title":"Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma","volume":"22","author":"Bohm","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2020.106655_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01789124","article-title":"Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion","volume":"36","author":"Hom","year":"1993","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2020.106655_b0115","first-page":"1767","article-title":"Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial","volume":"8","author":"Kono","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2020.106655_b0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF01789045","article-title":"Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors","volume":"32","author":"Shimizu","year":"1991","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2020.106655_b0125","doi-asserted-by":"crossref","first-page":"O2","DOI":"10.1186\/2051-1426-3-S2-O2","article-title":"Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes","volume":"3","author":"Gros","year":"2015","journal-title":"J. Immuno Ther. Cancer"},{"key":"10.1016\/j.intimp.2020.106655_b0130","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2020.106655_b0135","first-page":"3","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2020.106655_b0140","doi-asserted-by":"crossref","first-page":"e30852","DOI":"10.1371\/journal.pone.0030852","article-title":"Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization","volume":"7","author":"Baitsch","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2020.106655_b0145","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","article-title":"Expansion of tumor-infiltrating CD8(+) T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy","volume":"77","author":"Fernandez-Poma","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2020.106655_b0150","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106655_b0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/0008-5472.CAN-12-2606","article-title":"PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer","volume":"73","author":"Badoual","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2020.106655_b0160","doi-asserted-by":"crossref","first-page":"113345","DOI":"10.18632\/oncotarget.23007","article-title":"Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2020.106655_b0165","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2020.106655_b0170","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2020.106655_b0175","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","article-title":"Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion","volume":"193","author":"Ferris","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0180","doi-asserted-by":"crossref","first-page":"120207","DOI":"10.1155\/2015\/120207","article-title":"Current state of vascular resections in pancreatic cancer surgery","volume":"2015","author":"Hackert","year":"2015","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.intimp.2020.106655_b0185","doi-asserted-by":"crossref","first-page":"10953","DOI":"10.1038\/s41598-019-47548-z","article-title":"Treatment of splenic flexure colon cancer: a comparison of three different surgical procedures: Experience of a high volume cancer center","volume":"9","author":"Rega","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2020.106655_b0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2249.2008.03734.x","article-title":"Human spleen contains different subsets of dendritic cells and regulatory T lymphocytes","volume":"154","author":"Velasquez-Lopera","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01468720","article-title":"Number and distribution of lymphocytes in man. A critical analysis","volume":"52","author":"Trepel","year":"1974","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.intimp.2020.106655_b0200","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/modpathol.3800141","article-title":"Flow cytometric analysis of normal and reactive spleen","volume":"17","author":"Colovai","year":"2004","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2020.106655_b0205","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1309\/AJCPPIBH3I1VRWXQ","article-title":"Splenic lymphoid subsets with less well-recognized phenotypes mimic aberrant antigen expression","volume":"140","author":"Aggarwal","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2020.106655_b0210","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.intimp.2009.03.021","article-title":"Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells","volume":"9","author":"Donkor","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2020.106655_b0215","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.4049\/jimmunol.164.4.2214","article-title":"Resection of solid tumors reverses T cell defects and restores protective immunity","volume":"164","author":"Salvadori","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bjc.1994.20","article-title":"Constitutive production of multiple colony-stimulating factors in patients with lung cancer associated with neutrophilia","volume":"69","author":"Adachi","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2020.106655_b0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/jcp.43.6.461","article-title":"Preferential localisation of human lymphocytes bearing gamma delta T cell receptors to the red pulp of the spleen","volume":"43","author":"Bordessoule","year":"1990","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2020.106655_b0230","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.4049\/jimmunol.143.8.2480","article-title":"Distribution of T cells bearing different forms of the T cell receptor gamma\/delta in normal and pathological human tissues","volume":"143","author":"Falini","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0235","first-page":"55","article-title":"gamma delta T cells, their T cell receptor usage and role in human diseases","volume":"21","author":"Kabelitz","year":"1999","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.intimp.2020.106655_b0240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.imlet.2008.01.004","article-title":"Thymic production of human FOXP3(+) regulatory T cells is stable but does not correlate with peripheral FOXP3 expression","volume":"117","author":"Tuovinen","year":"2008","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2020.106655_b0245","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0250","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nri821","article-title":"CD4+ CD25+ suppressor T cells: more questions than answers","volume":"2","author":"Shevach","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0255","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri1032","article-title":"Natural versus adaptive regulatory T cells","volume":"3","author":"Bluestone","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0260","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/00007890-200004150-00016","article-title":"Induction of xenoreactive CD4+ T-cell anergy by suppressor CD8+CD28- T cells","volume":"69","author":"Colovai","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2020.106655_b0265","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0198-8859(02)00742-5","article-title":"Regulatory CD8+CD28- T cells in heart transplant recipients","volume":"64","author":"Colovai","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0270","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.micinf.2004.02.020","article-title":"Foxp3: a critical regulator of the development and function of regulatory T cells","volume":"6","author":"Hori","year":"2004","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2020.106655_b0275","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.intimp.2020.106655_b0280","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/intimm\/dxh165","article-title":"Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells","volume":"16","author":"Yagi","year":"2004","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0285","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/15384047.2018.1423919","article-title":"PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer","volume":"19","author":"Ren","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.intimp.2020.106655_b0290","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1084\/jem.194.12.1711","article-title":"Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells","volume":"194","author":"Geginat","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106655_b0295","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0369-8114(03)00098-1","article-title":"Cytokine-driven proliferation and differentiation of human naive, central memory and effector memory CD4+ T cells","volume":"51","author":"Geginat","year":"2003","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.intimp.2020.106655_b0300","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni889","article-title":"Lineage relationship and protective immunity of memory CD8 T cell subsets","volume":"4","author":"Wherry","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0305","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1108","article-title":"Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites","volume":"10","author":"Zaph","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2020.106655_b0310","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1615\/CritRevImmunol.v32.i2.10","article-title":"Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens","volume":"32","author":"Caserta","year":"2012","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0320","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2020.106655_b0325","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2020.106655_b0330","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106655_b0335","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nri2959","article-title":"Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?","volume":"11","author":"Akbar","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0340","doi-asserted-by":"crossref","first-page":"e17621","DOI":"10.1371\/journal.pone.0017621","article-title":"Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2020.106655_b0345","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2020.106655_b0350","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.106655_b0355","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/0008-5472.CAN-03-3066","article-title":"Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance","volume":"64","author":"Zippelius","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2020.106655_b0360","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin. Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920308353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920308353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:17:13Z","timestamp":1761585433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920308353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":72,"alternative-id":["S1567576920308353"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106655","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative phenotypes of peripheral blood and spleen cells from cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106655"}}